|
|
 |
 |
 |
 |
|
|
|
 Clinical and Scientific Calendar
- Society for Neuroscience
November 15 - 19, 2008
Washington Convention Center
Washington, DC
Sunday, November 16, 2008 from 1:00 - 5:00 p.m., #233
Presenter: Jenny Zhang, Ph.D, Sr. Scientist, Preclinical Research
Poster: Pharmacological characterization of functional upregulation of human alpha4beta2 neuronal nicotinic acetylcholine receptors by reduced temperature
Monday, November 17, 2008 at 8 a.m. - Noon, #328
Presenter: Vladimir Grinevich, M.D., Ph.D., Sr. Scientist
Poster: Effects of TC-5653, a potent alpha4*/alpha6* nicotinic receptor partial agonist, on striatal dopamine release
Monday, November 17, 2008 at 8 to 9:00 a.m., #329.5
Presenter: Teng Peng, AstraZeneca (Greg Gatto, Ph. D., Sr. Director, Preclinical Pharmacology; Vladimir Grinevich, M.D. Ph.D. and Terry Hauser, Ph.D., Group Leader, HTS and Neurochemistry, Preclinical Research, all of Targacept , are co-authors)
Poster: In vitro and in vivo binding of the potent radioligand, [3H]-2-FA and the agonist AZD3480 (TC-1734) at neuronal nicotinic receptors
- Pharma ChemOutsourcing Conference & Exhibition
September 8-9 2008
Ocean Place Resort
Long Branch, NJ
Tuesday, September 9, 2008, from 8:30 a.m. - 9:30 a.m.
Presenter: Michael G. Williams - Director, Pharmaceutical Research & Development
Presentation: How Will New Regulations in Asia Effect The Cost Sourcing?
Tuesday, September 9, 2008, from 2:15 p.m. - 3:30 p.m.
Presenter: Michael G. Williams - Director, Pharmaceutical Research & Development
Presentation: I Have to Scale UP to 20 Kilos in 6 Months - How Am I Going to Get This Done?
- American Chemical Society
August 17-21, 2008
Philadelphia Marriott
Philadelphia, PA
Monday, August 18, 2008, 1:30 p.m.
Presenter: Daniel Yohannes, Ph.D., Director, Drug Discovery
Presentation: Development of selective alpha7 NNR agonists for the treatment of schizophrenia
Monday, August 18, 2008 from 4:25 p.m.
Presenter: Daniel Yohannes, Ph.D., Director, Drug Discovery
Presentation: New Approaches for the Treatment of Schizophrenia
Thursday, August 21, 2008, 1:30 PM
Presenter: Craig Miller, Ph.D., Principal Scientist, Intellectual Property
Presentation: Comprehensive, systematic intellectual property capture and management
Thursday, August 21, 2008 from 3:30 PM to 4:00 PM
Presenter: Craig Miller, Ph.D., Principal Scientist, Intellectual Property
Presentation: The Many Faces of CHAL: Where Chemistry Meets the Law
- CINP 2008 - 50th Anniversary
July 13-17, 2008
Internationales Congress Center Munchen
Munich, Germany
Wednesday, July 16, 5:00 - 7:00 p.m.
Presenter: Geoffrey C. Dunbar, M.D.,Vice President, Clinical Development and Regulatory Affairs, Targacept
Poster: Effect of Nicotinic Antagonism on Irritability in Depressed Patients Who Were Partial or Non Responders to Citalopram First Line Therapy: A Mecamylamine Double Blind Placebo Controlled Study
- 2008 BIO International Convention
June 17-20, 2008
San Diego Convention Center
San Diego, CA
Tuesday, June 17, 4:00 - 5:30 p.m.
Panelist: Jeffrey Brennan, Vice-President, Business and Commercial Development, Targacept
Presentation: New Biotech-Pharma Partnership Models That Retain Greater Value
Wednesday, June 18, 10:15 - 11:45 a.m.
Panelist: Don deBethizy, Ph.D., President & CEO, Targacept
Presentation: The Early Bird Gets the Worm: Extracting Value out of Your Early-Stage Pipeline
- Nicotinic Acetylcholine Receptors 2008
April 23 - 28, 2008
Wellcome Trust Conference Center
Wellcome Trust Genome Campus
Hinxton
Cambridgeshire
Presenters: Merourane Bencherif, MD, Ph.D., Vice President, Preclinical Research and Pat Lippiello, Ph.D., Senior Director, Project Planning and Scientific Communication, Targacept
Poster: Differential Effects of TC-5214 [S-(+)-mecamylamine] and TC-5213
[R-(-)-mecamylamine] at Low and High Sensitivity Human a4b2 Nicotinic Receptors and in Animal Models of Depression and Anxiety
Presenter: Kristen Jordan, Ph.D., Group Leader, Behavioral Neuroscience
Poster: TC-6499: An Orally Effective and Selective alpha4beta2 Neuronal Nicotinic Receptor Agonist with Anti-allodynic Activity
-
April 6 - 10, 2008
Morial Convention Center
New Orleans, Louisiana
Presenter: David C. Kombo, Ph.D., Sr. Computational Scientist
Poster: Predicting Ligand Binding Affinity to the Rat alpha4beta2 Neuronal Nicotinic Receptor: Lessons from Bayesian Categorization Modeling
- American College of Neuropsychopharmacology - 46th Annual Meeting
December 9-13, 2007
Boca Raton Resort and Conference Center
Boca Raton, FL, USA
Presenter: Geoffrey C. Dunbar, M.D., Vice President, Clinical Development and Regulatory Affairs, Targacept
Monday, December 10, 2007, 5:30-7:30 p.m.
Poster: Mecamylamine in the treatment for depressed patients who were poor responders to citalopram first line therapy; a double-blind placebo controlled study
- Society for Neuroscience Annual Meeting
November 3-7, 2007
San Diego Convention Center
San Diego, CA, USA
Saturday, November 3, 2007 at 2 p.m., #39.2, Board F33
Presenter: Nikolai Fedorov, Ph.D., Sr. Staff Scientist, Electrophysiology
Poster: Differential Effects of TC-5214 [S-(+)-mecamylamine] and TC-5213
[R-(-)-mecamylamine] at Low and High Sensitivity Human a4b2 Nicotinic Receptors and in Animal Models of Depression and Anxiety
Saturday, November 3, 2007 at 3 pm, #39.7, Board F38
Presenter: Kristen Jordan, Ph.D., Group Leader, Behavioral Neuroscience
Poster: TC-6499: An Orally Effective and Selective alpha4beta2 Neuronal Nicotinic Receptor Agonist with Anti-allodynic Activity
Saturday, November 3, 2007 at 3 p.m., Annual Brain Awareness Campaign Event, Room 17 AB
Presenter: Debra Perret, Communications Coordinator
Poster: Got Brains? We Do! Bringing the Brain to Audiences in NC’s Triad Region
- Nicotinic Acetylcholine Receptors as Therapeutic Targets: Emerging Frontiers in Basic Research & Clinical Science
Satellite to the 2007 Meeting of the Society for Neuroscience
October 31 - November 2, 2007
San Diego Convention Center
San Diego, CA, USA
November 1, 10:25 AM – Session 2: Alzheimer’s Disease
Presenter: Geoffrey C. Dunbar, M.D., Vice President, Clinical Development and Regulatory Affairs, Targacept
Presentation: Targeting a4ß2 nAChRs to Treat Cognitive Impairments in the Elderly: Clinical Trials with TC-1734 (AZD-3480) in AAMI and MCI
November 2, 10:00 AM – Session 7: ADHD, Depression and Epilepsy
Presenter: Ramana Kuchibhatla, Ph.D., President & CEO, Ventureast Pharmaceutical Services
Presentation: Clinical Studies with Mecamylamine in MDD Patients Non-Responsive to First-Line SSRI Treatment
- Women's Cognitive Health: Continuing the Dialogue
Cutting Edge Translational Research
October 24-26, 2007
Graylyn International Conference Center of Wake Forest University
Winston-Salem, NC
Wendesday, October 25, 3:00 p.m.
Presenter: Geoffrey C. Dunbar, M.D., Vice President, Clinical Development and Regulatory Affairs
Presentation: Mecamylamine Augmentation Treatment in Major Depressive Disorder
- European College of Neuropsychopharmacology
October 13 - 17, 2007
Austria Center Vienna
Vienna, Austria
Tuesday, October 15, 12 noon - 2:00 PM
Presenter: Patrick Lippiello, Senior Director, Project Planning and Scientific Communication
Poster: Novel neuronal nicotinic receptor selective compounds for the treatment of acute, chronic and neuropathic pain
Tuesday, October 16, 12 noon - 2:00 PM
Presenter: Merouane Bencherif, M.D., Ph.D., Vice President, Preclinical Research
Poster: TC-4214 ((S)-(+) Mecamylamine) demonstrates antidepressant and anxiolytic effects in multiple animal models.
|
|
|
 |
|
 |
|
|
